Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : CDC panel recommends Pfizer booster shot for those over 65, high-risk groups

09/23/2021 | 05:22pm EDT

A Centers for Disease Control and Prevention advisory panel on Thursday voted to recommend a third Pfizer-BioNTech COVID-19 shot for those over 65 and certain groups with underlying medical conditions.

In a series of votes, the Advisory Committee on Immunization Practices said it favored of booster shots at least six months after the standard two-dose regimen for all people 65 years old and older, as well as those 18 to 64 with underlying medical conditions that put them at high risk for COVID-19

Long-term care facility residents also were included.

The panel voted against allowing the booster shots for those with frequent occupational and institutional exposure to the virus, such as healthcare workers.

The votes came after hours of meetings, which began Wednesday and included discussions about the efficacy of the Pfizer COVID-19 vaccine over time and the necessity of a booster.

The Food and Drug Administration gave its full approval Wednesday for booster shots along the same guidelines, but added those with occupational and institutional exposure.

The FDA and CDC's guidelines and recommendations have so far derailed the Biden administration's desires to begin offering booster shots to nearly everyone this week.

The full CDC must give its final approval before booster shots for the affected groups can start to be administered.

Last week, a group of FDA scientists said a third dose of Pfizer's vaccine likely increases antibodies in recipients and offers greater protection against COVID-19. However, they stopped short of saying the extra dose is needed by a majority of Americans.

They said that even with waning immunity over time, the two-shot regime of the Pfizer vaccine still largely protects against severe cases of COVID-19.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source US Top News

All news about PFIZER, INC.
05:23pPFIZER : States can reserve COVID-19 shots for younger kids next week
AQ
02:55pFDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
02:13pMODERNA : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different ..
RE
01:40pPFIZER : FDA panel endorses booster shot for J&J COVID-19 vaccine
AQ
01:11pMODERNA : U.S. FDA delays decision on Moderna's COVID-19 vaccine for adolescents - WSJ
RE
01:02pPFIZER : FDA panel takes up tough questions on J&J COVID-19 boosters
AQ
11:51aMODERNA : U.S. FDA advisers to vote on J&J COVID-19 vaccine booster
RE
11:07aTHE LATEST : Pfizer seeks European OK for child vaccines
AQ
11:02aPFIZER : BioNTech ask EU agency to OK vaccine for kids 5-11
AQ
10:55aPFIZER : BioNTech Makes European Medicines Agency Submission of Data Focusing COVID-19 Vac..
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 101 M - -
Net income 2021 18 457 M - -
Net Debt 2021 29 308 M - -
P/E ratio 2021 12,3x
Yield 2021 3,80%
Capitalization 234 B 234 B -
EV / Sales 2021 3,24x
EV / Sales 2022 3,70x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 41,49 $
Average target price 45,72 $
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.13.20%233 631
JOHNSON & JOHNSON2.49%421 487
ROCHE HOLDING AG15.58%336 383
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.89%214 579
MERCK & CO., INC.-4.24%198 283